Clinical Trial Update: A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating zanidatamab plus physician's choice chemotherapy versus trastuzumab plus chemotherapy in metastatic HER2-positive breast cancer; recr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Trastuzumab (trastuzumab)
• Zanidatamab (ZW25) (zanidatamab)

Snippet

Sponsor: Jazz Pharmaceuticals | Conditions: Metastatic HER2-positive Breast Cancer | Phase 3 | Status: RECRUITING